Classification of HIV protease inhibitors on the basis of their antiviral potency using radial basis function neural networks.

J Comput Aided Mol Des

Department of Chemistry, 152 Davey Laboratory, Penn State University, University Park, PA 16802, USA.

Published: April 2004

HIV protease inhibitors are being used as frontline therapy in the treatment of HIV patients. Multi-drug-resistant HIV mutant strains are emerging with the initial aggressive multi-drug treatment of HIV patients. This necessitates continued search for novel inhibitors of viral replication. These protease inhibitors may further be useful as pharmacological agents for inhibition of other viral replication. Classification models of HIV Protease inhibitors are developed using a data set of 123 compounds containing several heterocycles. Their inhibitory concentrations expressed as log (IC50) ranged from -1.52 to 2.12 log units. The dataset was divided into active and inactive classes on the basis of their antiviral potency. Initially a two-class problem (active, inactive) is explored using k-nearest neighbor approach. In order to introduce non-linearity in the classifier different approaches were investigated. This led to the goal of a fast, simple, minimum user input, radial basis function neural network (RBFNN) classifier development. Then the same two-class problem was resolved using the (RBFNN) classifier. A genetic algorithm with RBFNN fitness evaluator was used to search for the optimum descriptor subsets. The application of majority rules was also tested for the RBFNN classification. The best six descriptor model found by the new cost function showed predictive ability in the high 80% range for an external prediction set.

Download full-text PDF

Source
http://dx.doi.org/10.1023/a:1025317806473DOI Listing

Publication Analysis

Top Keywords

protease inhibitors
16
hiv protease
12
basis antiviral
8
antiviral potency
8
radial basis
8
basis function
8
function neural
8
treatment hiv
8
hiv patients
8
viral replication
8

Similar Publications

Introduction: This study aimed to analyze the levels of MMP-9 and TIMP-1 as biomarkers for identifying lung anatomical and functional abnormalities in coronavirus disease 2019 (COVID-19).

Methodology: Adult COVID-19 patients hospitalized between October and December 2021 were included in the study. MMP-9 and TIMP-1 levels were measured from the blood.

View Article and Find Full Text PDF

The process of viral entry into host cells is crucial for the establishment of infection and the determination of viral pathogenicity. A comprehensive understanding of entry pathways is fundamental for the development of novel therapeutic strategies. Standard techniques for investigating viral entry include confocal microscopy and flow cytometry, both of which provide complementary qualitative and quantitative data.

View Article and Find Full Text PDF

Chronic lymphocytic leukemia is a malignant lymphoproliferative disorder for which primary or acquired drug resistance represents a major challenge. To investigate the underlying molecular mechanisms, we generate a mouse model of ibrutinib resistance, in which, after initial treatment response, relapse under therapy occurrs with an aggressive outgrowth of malignant cells, resembling observations in patients. A comparative analysis of exome, transcriptome and proteome of sorted leukemic murine cells during treatment and after relapse suggests alterations in the proteasome activity as a driver of ibrutinib resistance.

View Article and Find Full Text PDF

Background: People with subclinical atrial fibrillation are at increased risk of stroke, albeit to a lesser extent than those with clinical atrial fibrillation, leading to an ongoing debate regarding the benefit of anticoagulation in these individuals. In the ARTESiA trial, the direct-acting oral anticoagulant apixaban reduced stroke or systemic embolism compared with aspirin in people with subclinical atrial fibrillation, but the risk of major bleeding was increased with apixaban. In a prespecified subgroup analysis of ARTESiA, we tested the hypothesis that people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack, who are known to have an increased risk of recurrent stroke, would show a greater benefit from oral anticoagulation for secondary stroke prevention compared with those without a history of stroke or transient ischaemic attack.

View Article and Find Full Text PDF

Endocan as a marker of endotheliitis in COVID-19 patients: modulation by veno-venous extracorporeal membrane oxygenation, arterial hypertension and previous treatment with renin-angiotensin-aldosterone system inhibitors.

Inflamm Res

January 2025

Departamento de Biomedicina - Unidade de Farmacologia e Terapêutica, Faculdade de Medicina da Universidade do Porto (FMUP), Rua Dr. Plácido da Costa, S/N, Edifício Poente, Piso 3, 4200-450, Porto, Portugal.

Background And Aims: Endocan has been scarcely explored in COVID-19, especially regarding its modulation by veno-venous extracorporeal membrane oxygenation (VV-ECMO), hypertension or previous renin-angiotensin-aldosterone system (RAAS) inhibitors treatment. We compared endocan and other endotheliitis markers in hospitalized COVID-19 patients and assessed their modulation by VV-ECMO, hypertension and previous RAAS inhibitors treatment.

Material And Methods: Serum endocan, intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin were measured in "severe" (n = 27), "critically ill" (n = 17) and "critically ill on VV-ECMO" (n = 17) COVID-19 patients at admission, days 3-4, 5-8 and weekly thereafter, and in controls (n = 23) at a single time point.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!